|
SE0202463D0
(sv)
|
2002-08-14 |
2002-08-14 |
Astrazeneca Ab |
Novel compounds
|
|
BRPI0611863B1
(pt)
|
2005-06-22 |
2021-11-23 |
Plexxikon, Inc |
Composto, bem como composição e kit compreendendo o mesmo, composto intermediário na preparação do mesmo, método para tratamento e uso do mesmo
|
|
US20130210034A1
(en)
|
2005-11-04 |
2013-08-15 |
Beckman Coulter, Inc. |
Complex phosphoprotein activation profiles
|
|
US20070105165A1
(en)
|
2005-11-04 |
2007-05-10 |
Charles Goolsby |
Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers
|
|
US7812143B2
(en)
|
2006-03-31 |
2010-10-12 |
Memorial Sloan-Kettering Cancer Center |
Biomarkers for cancer treatment
|
|
KR20090071603A
(ko)
|
2006-09-19 |
2009-07-01 |
노파르티스 아게 |
Ｒａｆ 억제제에 대한 표적 조절, 효능, 진단 및/또는 예후의 바이오마커
|
|
WO2008120004A1
(en)
|
2007-04-02 |
2008-10-09 |
Astrazeneca Ab |
Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
|
|
EP1977765A1
(en)
|
2007-04-03 |
2008-10-08 |
Diatos |
Peptide prodrugs
|
|
WO2008148522A2
(en)
|
2007-06-04 |
2008-12-11 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Method to identify modulators of b-raf protein kinase and their use for the treatment of anxiety and depression
|
|
CA2639416C
(en)
|
2007-09-11 |
2019-12-31 |
F. Hoffmann-La Roche Ag |
Diagnostic test for susceptibility to b-raf kinase inhibitors
|
|
EP2294769B1
(en)
|
2008-07-01 |
2012-10-24 |
Telefonaktiebolaget L M Ericsson (PUBL) |
Methods and apparatus using precoding matrices in a mimo telecommunications system
|
|
CA2729914A1
(en)
|
2008-07-11 |
2010-01-14 |
Novartis Ag |
Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway
|
|
WO2010056662A1
(en)
|
2008-11-11 |
2010-05-20 |
University Of Washington |
Activated wnt-beta-catenin signaling in melanoma
|
|
US9084781B2
(en)
|
2008-12-10 |
2015-07-21 |
Novartis Ag |
MEK mutations conferring resistance to MEK inhibitors
|
|
CN102421776A
(zh)
|
2009-03-11 |
2012-04-18 |
普莱希科公司 |
抑制Raf激酶的吡咯并[2，3-b]吡啶衍生物
|
|
WO2010111527A1
(en)
|
2009-03-26 |
2010-09-30 |
Plexxikon, Inc. |
Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
|
|
AR078033A1
(es)
|
2009-04-03 |
2011-10-12 |
Plexxikon Inc |
Una dispersion solida, que contiene al compuesto {3-[5-(4-(cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico, composiciones y formulaciones que comprenden a dicha dispersion solida; metodos para fabricar dicha dispersion solida, formas 1 y 2 de
|
|
TW201041888A
(en)
|
2009-05-06 |
2010-12-01 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
|
US8329724B2
(en)
|
2009-08-03 |
2012-12-11 |
Hoffmann-La Roche Inc. |
Process for the manufacture of pharmaceutically active compounds
|
|
EP2461835A4
(en)
|
2009-08-07 |
2013-05-15 |
Wistar Inst |
COMPOSITIONS WITH JARID1B INHIBITORS AND METHOD FOR THE TREATMENT OF CANCER
|
|
EP2467491A4
(en)
|
2009-08-21 |
2014-04-02 |
Sinai School Medicine |
METHODS OF USING CD44 FUSION PROTEINS TO TREAT CANCER
|
|
WO2011060216A1
(en)
|
2009-11-12 |
2011-05-19 |
Concert Pharmaceuticals Inc. |
Substituted azaindoles
|
|
WO2011079133A2
(en)
|
2009-12-23 |
2011-06-30 |
Plexxikon, Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
US9180127B2
(en)
|
2009-12-29 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Type II Raf kinase inhibitors
|
|
WO2011097594A2
(en)
|
2010-02-08 |
2011-08-11 |
Kinagen, Inc. |
Therapeutic methods and compositions involving allosteric kinase inhibition
|
|
ES2714875T3
(es)
|
2010-03-09 |
2019-05-30 |
Dana Farber Cancer Inst Inc |
Métodos de diagnóstico y tratamiento del cáncer en pacientes que presentan o desarrollan resistencia a una primera terapia del cáncer
|
|
ES2677356T3
(es)
|
2010-03-24 |
2018-08-01 |
Amitech Therapeutics Solutions, Inc. |
Compuestos heterocíclicos útiles para la inhibición de quinasas
|
|
EA028080B1
(ru)
|
2010-06-09 |
2017-10-31 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Мутация в mek1, придающая устойчивость к ингибиторам raf и mek
|
|
US9125899B1
(en)
|
2010-06-17 |
2015-09-08 |
Stc.Unm |
Modulators of GTPases and their use
|
|
US8779150B2
(en)
|
2010-07-21 |
2014-07-15 |
Hoffmann-La Roche Inc. |
Processes for the manufacture of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1 H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide
|
|
US8980549B2
(en)
|
2010-08-01 |
2015-03-17 |
Ramot At Tel Aviv University Ltd. |
MicroRNA patterns for the diagnosis, prognosis and treatment of melanoma
|
|
WO2012021778A2
(en)
|
2010-08-12 |
2012-02-16 |
The Regents Of The University Of California |
Methods for blocking cell proliferation and treating diseases and conditions responsive to cell growth inhibition
|
|
US20120045433A1
(en)
|
2010-08-17 |
2012-02-23 |
Kapil Dhingra |
Combination therapy
|
|
US8709419B2
(en)
|
2010-08-17 |
2014-04-29 |
Hoffmann-La Roche, Inc. |
Combination therapy
|
|
WO2012027536A1
(en)
|
2010-08-26 |
2012-03-01 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseases
|
|
WO2012027716A1
(en)
|
2010-08-27 |
2012-03-01 |
Collabrx, Inc. |
Method to treat melanoma in braf inhibitor-resistant subjects
|
|
WO2012030738A2
(en)
|
2010-08-30 |
2012-03-08 |
Beckman Coulter, Inc. |
Complex phosphoprotein activation profiles
|
|
US9089570B2
(en)
|
2010-09-03 |
2015-07-28 |
Tactical Therapeutics Inc |
Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
|
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
|
US20120208837A1
(en)
|
2010-09-13 |
2012-08-16 |
Roger Tung |
Substituted azaindoles
|
|
US20120064135A1
(en)
|
2010-09-15 |
2012-03-15 |
Norac Pharma |
Benzoyl Peroxide Composition, Methods for Making Same, and Pharmaceutical or Cosmetic Formulations Comprising Same, and Uses Thereof
|
|
US9297812B2
(en)
|
2010-09-30 |
2016-03-29 |
Deutsches Krebsforschungzentrum |
Means and methods for diagnosing cancer using an antibody which specifically binds to BRAF V600E
|
|
US20120095078A1
(en)
|
2010-10-07 |
2012-04-19 |
Sanford-Burnham Medical Research Institute |
Methods of diagnosis and treatment of melanoma
|
|
US20120108457A1
(en)
|
2010-10-11 |
2012-05-03 |
Sanford-Burnham Medical Research Institute |
Mir-211 expression and related pathways in human melanoma
|
|
US20140134231A1
(en)
|
2010-10-11 |
2014-05-15 |
Sanford-Burnham Medical Research Institute |
Mir-211 expression and related pathways in human melanoma
|
|
US20120276122A1
(en)
|
2010-11-01 |
2012-11-01 |
Sanford-Burnham Medical Research Institute |
Methods for diagnosis and treatment of cellular proliferative disorders
|
|
EP2640860A4
(en)
|
2010-11-19 |
2014-06-04 |
Univ California |
COMPOSITIONS AND METHODS FOR DETECTING AND TREATING B-RAF HEMMER RESISTANT MELANOMES
|
|
CN104689318A
(zh)
|
2010-11-19 |
2015-06-10 |
葛兰素史密斯克莱知识产权（第2号）有限公司 |
使用braf抑制剂的治疗方法
|
|
EP2643699A4
(en)
|
2010-11-22 |
2014-05-28 |
Univ Nova Southeastern |
ONCOLYTIC VSV MODULATION AND UPGRADING OF RAE1 AND NUP98 WITH STATINS
|
|
US9296811B2
(en)
|
2010-12-02 |
2016-03-29 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Methods for treating a tumor using an antibody that specifically binds HMW-MAA
|
|
US9295669B2
(en)
|
2010-12-14 |
2016-03-29 |
Hoffman La-Roche Inc. |
Combination therapy for proliferative disorders
|
|
US20130004481A1
(en)
|
2011-01-12 |
2013-01-03 |
Boehringer Ingelheim International Gmbh |
Anticancer therapy
|
|
MA34948B1
(fr)
|
2011-02-07 |
2014-03-01 |
Plexxikon Inc |
Composes et procedes de modulation de kinase, et leurs indications
|
|
EP2672963A4
(en)
|
2011-02-08 |
2015-06-24 |
Childrens Medical Center |
METHOD FOR THE TREATMENT OF MELANOMA
|
|
TWI558702B
(zh)
|
2011-02-21 |
2016-11-21 |
普雷辛肯公司 |
醫藥活性物質的固態形式
|
|
RU2568258C2
(ru)
|
2011-02-28 |
2015-11-20 |
Саншайн Лейк Фарма Ко., Лтд |
Замещенные соединения хинолина и способы их использования
|
|
WO2012117396A1
(en)
|
2011-03-01 |
2012-09-07 |
Novotyr Therapeutics Ltd |
Tyrphostin derivative in combination with cytotoxic compounds for treating cancer
|
|
WO2012119095A1
(en)
|
2011-03-02 |
2012-09-07 |
Board Of Regents, The University Of Texas System |
Fus1/tusc2 therapies
|
|
JP6322413B2
(ja)
|
2011-03-10 |
2018-05-09 |
プロヴェクタス ファーマテック，インク． |
改善されたがん治療のための局所および全身性免疫修飾療法の組み合わせ
|
|
CN103857395A
(zh)
|
2011-04-01 |
2014-06-11 |
基因泰克公司 |
Akt抑制剂化合物和阿比特龙的组合及使用方法
|
|
EP2694677A2
(en)
|
2011-04-04 |
2014-02-12 |
Netherland Cancer Institute |
Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
|
|
US8680066B2
(en)
|
2011-04-05 |
2014-03-25 |
The United States of America as represented by the Development of Veterans Affairs |
Methods for determining and inhibiting rheumatoid arthritis associated with the BRAF oncogene in a subject
|
|
WO2012138809A1
(en)
|
2011-04-05 |
2012-10-11 |
Dawei Zhang |
Heterocyclic compounds as kinase inhibitors
|
|
EP2508607A1
(en)
|
2011-04-07 |
2012-10-10 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Medicament for liver regeneration and for treatment of liver failure
|
|
EP2694504A4
(en)
|
2011-04-08 |
2014-08-27 |
Afraxis Holdings Inc |
8-ETHYL-6 (ARYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF DISEASES AFFECTING THE NERVOUS SYSTEM AND FOR THE TREATMENT OF CANCER
|
|
CA2828946C
(en)
|
2011-04-18 |
2016-06-21 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
|
WO2012145503A1
(en)
|
2011-04-21 |
2012-10-26 |
Novartis Ag |
Pharmaceutical combinations
|
|
GB201107197D0
(en)
|
2011-04-28 |
2011-06-15 |
Cxr Biosciences Ltd |
Compounds
|
|
US9592236B2
(en)
|
2011-04-28 |
2017-03-14 |
Duke University |
Methods of treating hemoglobinopathies
|
|
GB201107176D0
(en)
|
2011-04-28 |
2011-06-15 |
Cxr Biosciences Ltd |
Pyrrolnitrin derivatives
|
|
EP2702054B1
(en)
|
2011-04-29 |
2018-10-24 |
The Trustees of The University of Pennsylvania |
Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use
|
|
US9221760B2
(en)
|
2011-05-09 |
2015-12-29 |
Van Andel Research Institute |
Autophagy inhibitors
|
|
WO2012154858A1
(en)
|
2011-05-09 |
2012-11-15 |
Whitehead Institute For Biomedical Research |
Chaperone interaction assays and uses thereof
|
|
AU2012253525B2
(en)
|
2011-05-10 |
2016-09-22 |
Brunangelo Falini |
Hairy cell leukemia biomarkers and methods of using same
|
|
US20140127316A1
(en)
|
2011-05-20 |
2014-05-08 |
New York University |
Propolis and caffeic acid phenethyl ester and uses thereof
|
|
US9481910B2
(en)
|
2011-05-25 |
2016-11-01 |
Memorial Sloan-Kettering Cancer Center |
Methods and compositions for the detection of drug resistant BRAF isoforms
|
|
WO2012166949A1
(en)
|
2011-05-31 |
2012-12-06 |
Regents Of The University Of Minnesota |
Silicate prodrugs and nanoparticles
|
|
EP3446714B1
(en)
|
2011-06-02 |
2021-03-31 |
University of Louisville Research Foundation, Inc. |
Anti-nucleolin agent-conjugated nanoparticles
|
|
EP3326616B1
(en)
|
2011-06-03 |
2021-07-28 |
Signpath Pharma Inc. |
Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current
|
|
CA2838387A1
(en)
|
2011-06-06 |
2012-12-13 |
Chevron Phillips Chemical Company Lp |
Use of metallocene compounds for cancer treatment
|
|
CA2838736A1
(en)
|
2011-06-07 |
2012-12-13 |
Caris Mpi, Inc. |
Molecular profiling for cancer
|
|
US20120321637A1
(en)
|
2011-06-20 |
2012-12-20 |
The Board Of Regents Of The University Of Texas System |
Combination cancer therapy with herv inhibition
|
|
US20140348819A1
(en)
|
2011-06-24 |
2014-11-27 |
Dana-Farber Cancer Institute, Inc. |
Methods of Treating Cancer
|
|
EP2570127A1
(en)
|
2011-09-16 |
2013-03-20 |
Sanofi |
Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors
|
|
CN103930111A
(zh)
|
2011-09-19 |
2014-07-16 |
霍夫曼-拉罗奇有限公司 |
包含c-met拮抗剂和b-raf拮抗剂的组合治疗
|
|
WO2013044169A1
(en)
|
2011-09-21 |
2013-03-28 |
Nestec S.A. |
Methods for determining combination therapy with il-2 for the treatment of cancer
|
|
WO2013052608A1
(en)
|
2011-10-07 |
2013-04-11 |
Sanford-Burnham Medical Research Institute |
Optically pure apogossypolone derivatives as pan-active inhibitors of anti-apoptotic bcl-2 family proteins
|
|
MX2014004991A
(es)
|
2011-10-28 |
2014-05-22 |
Genentech Inc |
Combinaciones terapeuticas y metodos para tratar el melanoma.
|
|
CA2854188A1
(en)
|
2011-11-14 |
2013-05-23 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors with braf inhibitors
|
|
GB201121869D0
(en)
|
2011-11-17 |
2012-02-01 |
Clarient Inc |
Method of allele-specific amplification
|
|
US9284337B2
(en)
|
2011-11-22 |
2016-03-15 |
Trustees Of Tufts College |
Small molecule enhancer for dendritic cell cancer vaccines
|
|
CN104080461A
(zh)
|
2011-11-30 |
2014-10-01 |
雪松-西奈医学中心 |
靶向微小rna mir-409-5p、mir-379和mir-154*来治疗前列腺癌骨转移和耐药性肺癌
|
|
US9408885B2
(en)
|
2011-12-01 |
2016-08-09 |
Vib Vzw |
Combinations of therapeutic agents for treating melanoma
|
|
EP2788378A4
(en)
|
2011-12-09 |
2015-09-09 |
Oncomed Pharm Inc |
ASSOCIATION THERAPY FOR THE TREATMENT OF CANCER
|
|
US20130172375A1
(en)
|
2011-12-13 |
2013-07-04 |
Hoffmann-La Roche Inc. |
Pharmaceutical composition
|
|
EP2802314B1
(en)
|
2012-01-13 |
2020-11-25 |
XSpray Microparticles AB |
A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.
|
|
WO2013109142A1
(en)
|
2012-01-16 |
2013-07-25 |
Stichting Het Nederlands Kanker Instituut |
Combined pdk and mapk/erk pathway inhibition in neoplasia
|
|
WO2013116228A1
(en)
|
2012-01-31 |
2013-08-08 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Compounds and methods for inhibition of ap endonuclease-1/ redox factor-1 (hape1) activity
|
|
CN104185681A
(zh)
|
2012-02-01 |
2014-12-03 |
卡姆普根有限公司 |
C1orf32抗体及其用于治疗癌症的用途
|
|
WO2013123463A1
(en)
|
2012-02-15 |
2013-08-22 |
The Translational Genomics Research Institute |
A system and method of genomic profiling
|
|
EP2817004B1
(en)
|
2012-02-22 |
2018-04-11 |
The Regents of The University of Colorado, A Body Corporate |
Bouvardin derivatives and therapeutic uses thereof
|
|
EP2820041B1
(en)
|
2012-03-02 |
2017-06-14 |
Ludwig Institute For Cancer Research Ltd. |
Iaspp phosphorylation and metastatic potential
|
|
EP2822926A4
(en)
|
2012-03-07 |
2015-11-04 |
H Lee Moffitt Cancer Ct & Res |
SELECTIVE HISTON DEACTY LASE-6 HEMMER
|
|
EP2823307A4
(en)
|
2012-03-08 |
2015-07-29 |
Bioscale Inc |
METHOD AND KITS FOR ANALYZING BIOMARKERS IN A SIGNAL TRANSDUCTION PATH
|
|
AU2013201584A1
(en)
|
2012-03-12 |
2013-09-26 |
Merrimack Pharmaceuticals, Inc. |
Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody
|
|
WO2013138210A1
(en)
|
2012-03-14 |
2013-09-19 |
Ning Xi |
Substituted cyclic compounds and methods of use
|
|
WO2013138753A1
(en)
|
2012-03-16 |
2013-09-19 |
Fox Chase Chemical Diversity Center, Inc. |
Prodrugs of riluzole and their method of use
|
|
US9216170B2
(en)
|
2012-03-19 |
2015-12-22 |
Hoffmann-La Roche Inc. |
Combination therapy for proliferative disorders
|
|
US9358235B2
(en)
|
2012-03-19 |
2016-06-07 |
Plexxikon Inc. |
Kinase modulation, and indications therefor
|
|
KR101497972B1
(ko)
|
2012-03-21 |
2015-03-03 |
서울대학교산학협력단 |
Ｎｏｄ2 신호전달 경로를 표적으로 하는 패혈증 치료제 스크리닝 방법 및 패혈증 치료제
|
|
US9464326B2
(en)
|
2012-03-22 |
2016-10-11 |
University Of Maryland, Baltimore |
Total and phosphorylated IL-1 receptor-associated kinase-1 and IL-1 receptor-associated kinase-4 as a biomarker for cancer progression and chemotherapy resistance
|
|
BR112014023496A2
(pt)
|
2012-03-28 |
2017-07-18 |
Dana Farber Cancer Inst Inc |
mutantes c-raf que conferem resistência a inibidores de raf
|
|
WO2013148537A1
(en)
|
2012-03-29 |
2013-10-03 |
Ning Xi |
Substituted spirobicyclic compounds and methods of use
|
|
AU2013240191B2
(en)
|
2012-03-29 |
2018-02-22 |
Altor Bioscience Corporation |
Methods for treating neoplasia
|
|
WO2013152034A1
(en)
|
2012-04-02 |
2013-10-10 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
|
|
US20130288980A1
(en)
|
2012-04-02 |
2013-10-31 |
Buck Institute For Research On Aging |
Targeting senescent and cancer cells for selective killing by interference with foxo4
|
|
US20130288981A1
(en)
|
2012-04-02 |
2013-10-31 |
Buck Institute For Research On Aging |
Targeting senescent cells and cancer cells by interference with jnk and/or foxo4
|
|
WO2013155077A1
(en)
|
2012-04-09 |
2013-10-17 |
Board Of Regents,The University Of Texas System |
Response markers for src inhibitor therapies
|
|
WO2013165320A1
(en)
|
2012-05-04 |
2013-11-07 |
Agency For Science, Technology And Research |
Treating cancer by increasing expression of socs6
|
|
WO2013169858A1
(en)
|
2012-05-08 |
2013-11-14 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
|
|
KR20150006477A
(ko)
|
2012-05-09 |
2015-01-16 |
그래댈리스, 인코포레이티드 |
단일-뉴클레오타이드 ｋｒａｓ 돌연변이에 특이적인 이-기능성 짧은-헤어핀 ｒｎａ (ｂｉ-ｓｈｒｎａ)
|
|
WO2013170159A1
(en)
|
2012-05-10 |
2013-11-14 |
Synta Pharmaceuticals Corp. |
Treating cancer with hsp90 inhibitory compounds
|
|
US20150126621A1
(en)
|
2012-05-15 |
2015-05-07 |
New York University |
METHOD FOR PREDICTING RECURRENCE OF MELANOMA USING miRNA ALTERATIONS
|
|
WO2013171753A1
(en)
|
2012-05-16 |
2013-11-21 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Methods of treating and diagnosing diseases using agents that regulate the alternative splicing pathway
|
|
WO2013173644A2
(en)
|
2012-05-16 |
2013-11-21 |
John Wayne Cancer Institute |
Immunological markers for adjuvant therapy in melanoma
|
|
WO2013177092A1
(en)
|
2012-05-23 |
2013-11-28 |
Sunshine Lake Pharma Co., Ltd. |
Substituted alkynyl pyridine compounds and methods of use
|
|
WO2013180949A1
(en)
|
2012-05-27 |
2013-12-05 |
Ning Xi |
Substituted quinoline compounds and methods of use
|
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
|
US20130330761A1
(en)
|
2012-06-12 |
2013-12-12 |
Celcuity, LLC |
Whole cell assays and methods
|
|
US20130336889A1
(en)
|
2012-06-14 |
2013-12-19 |
National Taiwan University |
Nanoparticle and method for detecting or treating a tumor using the same
|
|
US9220695B2
(en)
|
2012-06-29 |
2015-12-29 |
The Research Foundation For The State University Of New York |
Polyenolic zinc-binding agents (pezbins) actively promote inactivation of cancer stem cells and potentiate cytotoxic anti-tumor drug substances
|
|
EP2869824B1
(en)
|
2012-07-03 |
2024-03-27 |
Fondazione Centro San Raffaele |
2-deoxyglucose for use in the treatment of autosomal dominant polycystic kidney disease or polycystic liver disease
|
|
JP2015522037A
(ja)
|
2012-07-03 |
2015-08-03 |
ラシオファルム ゲーエムベーハー |
ベムラフェニブコリン塩の固体形態
|
|
WO2014009319A1
(en)
|
2012-07-11 |
2014-01-16 |
Boehringer Ingelheim International Gmbh |
Indolinone derivatives anticancer compounds
|
|
WO2014009318A1
(en)
|
2012-07-11 |
2014-01-16 |
Boehringer Ingelheim International Gmbh |
3-{3-[1 -(4-dimethylaminomethyl-phenylamino)-1 -phenyl-meth-(z)-ylidene]-2-oxo-2,3-dihydro-1 h-indol-6-yll-propynoic acid ethylamide and its use in the treatment of cancer
|
|
GB201212586D0
(en)
|
2012-07-16 |
2012-08-29 |
Univ Murcia |
Cancer treatment
|
|
MX2015001194A
(es)
|
2012-07-27 |
2015-11-23 |
Izumi Technology Llc |
Composiciones inhibidoras de eflujo y metodos de tratamiento que usan las mismas.
|
|
WO2014018862A1
(en)
|
2012-07-27 |
2014-01-30 |
Corning Incorporated |
Pharmaceutical compositions comprising a heat shock protein inhibitor and a|purine de novo synthesis inhibitor for treating rheumatoid arthritis or cancer
|
|
WO2014022116A2
(en)
|
2012-07-28 |
2014-02-06 |
Calitor Sciences, Llc |
Substituted pyrazolone compounds and methods of use
|
|
WO2014022128A1
(en)
|
2012-07-29 |
2014-02-06 |
Calitor Sciences, Llc |
Pi3 kinase modulators and methods of use
|
|
CA2918608A1
(en)
|
2012-08-03 |
2014-02-06 |
Icahn School Of Medicine At Mount Sinai |
Biomarker associated with risk of melanoma reoccurrence
|
|
WO2014028461A2
(en)
|
2012-08-13 |
2014-02-20 |
The Rockefeller University |
Treatment and diagnosis of melanoma
|
|
US20140045883A1
(en)
|
2012-08-13 |
2014-02-13 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Ack1 kinase inhibition to treat triple negative breast cancer
|
|
BR112015003418A2
(pt)
|
2012-08-17 |
2017-07-04 |
Hoffmann La Roche |
produto farmacêutico, conjunto, métodos para estender a duração da resposta ao tratamento, de retardar ou prevenir o desenvolvimento de resistência ao tratamento, para a seleção de uma terapia e para otimizar a eficácia terapêutica.
|
|
WO2014031856A1
(en)
|
2012-08-23 |
2014-02-27 |
Onconthyreon Inc. |
Combination therapy using pi3 kinase and braf inhibitors
|
|
TWI601725B
(zh)
|
2012-08-27 |
2017-10-11 |
加拓科學公司 |
取代的氮雜吲哚化合物及其鹽、組合物和用途
|
|
US9561266B2
(en)
|
2012-08-31 |
2017-02-07 |
University Of Virginia Patent Foundation |
Target peptides for immunotherapy and diagnostics
|
|
US9561245B2
(en)
|
2012-09-06 |
2017-02-07 |
The Board Of Regents Of The University Of Texas System |
Combination treatments for melanoma
|
|
CA2885230C
(en)
|
2012-09-19 |
2021-08-03 |
Anthony Letai |
Dynamic bh3 profiling
|
|
CA2886397A1
(en)
|
2012-09-26 |
2014-04-03 |
Insight Genetics, Inc. |
Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers
|
|
CN103172744B
(zh)
|
2012-09-28 |
2016-01-13 |
武汉纽斯特生物技术有限公司 |
特异性识别B-Raf突变蛋白的单克隆抗体、制备方法及其应用
|
|
CA2887058C
(en)
|
2012-10-03 |
2022-02-22 |
Exosome Diagnostics, Inc. |
Use of microvesicles in diagnosis, prognosis, and treatment of medical diseases and conditions
|
|
AU2013326463B2
(en)
|
2012-10-04 |
2018-01-18 |
Ab Science |
Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors
|
|
EA028605B1
(ru)
|
2012-10-08 |
2017-12-29 |
Атрива Терапьютикс Гмбх |
Комбинация озельтамивира и ингибитора mek для лечения вирусных заболеваний
|
|
EP2906712A1
(en)
|
2012-10-10 |
2015-08-19 |
Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis |
Methods and means for predicting resistance to anti-cancer treatment
|
|
CN104994861B
(zh)
|
2012-10-18 |
2019-10-11 |
西澳大学 |
使用miRNA的癌症疗法
|
|
WO2014072357A1
(en)
|
2012-11-06 |
2014-05-15 |
Interna Technologies B.V. |
Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
|
|
RU2015121367A
(ru)
|
2012-11-08 |
2017-01-10 |
Новартис Аг |
Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний
|
|
US20140147411A1
(en)
|
2012-11-14 |
2014-05-29 |
U.S. GOVERNMENT represented by the UNITED STATES DEPARTMENT OF VETERANS AFFAIRS |
Methods of treating cancer and testing mutation zygosity related thereto
|
|
TWI574962B
(zh)
|
2012-11-14 |
2017-03-21 |
加拓科學公司 |
作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
|
|
AU2013202507B9
(en)
|
2012-11-14 |
2015-08-13 |
Celgene Corporation |
Inhibition of drug resistant cancer cells
|
|
US9073878B2
(en)
|
2012-11-21 |
2015-07-07 |
Zenith Epigenetics Corp. |
Cyclic amines as bromodomain inhibitors
|
|
WO2014080291A2
(en)
|
2012-11-21 |
2014-05-30 |
Rvx Therapeutics Inc. |
Biaryl derivatives as bromodomain inhibitors
|
|
US20150290235A1
(en)
|
2012-11-23 |
2015-10-15 |
Ab Science |
Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
|
|
AU2012395148B2
(en)
|
2012-11-24 |
2016-10-27 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
|
WO2014089280A1
(en)
|
2012-12-07 |
2014-06-12 |
Calitor Sciences, Llc |
Alkynyl compounds and methods of use
|
|
WO2014089324A1
(en)
|
2012-12-07 |
2014-06-12 |
Calitor Sciences, Llc |
Substituted cyclic compounds and methods of use
|
|
US9945863B2
(en)
|
2012-12-14 |
2018-04-17 |
The Research Foundation Of State University Of New York |
Coiled coil helix cristae morphology 1 (CHCM1) tumor marker and cancer therapeutic target
|
|
RU2705556C2
(ru)
|
2012-12-21 |
2019-11-07 |
Келверум Инк. |
Нереплицируемые происходящие от вирусов частицы и их применение
|
|
CA2895905A1
(en)
|
2012-12-21 |
2014-06-26 |
Zenith Epigenetics Corp. |
Novel heterocyclic compounds as bromodomain inhibitors
|
|
CN107236816A
(zh)
|
2012-12-27 |
2017-10-10 |
奎斯特诊断投资股份有限公司 |
Ddr2突变作为黑素瘤或基底细胞癌的可靶向的特征
|
|
US20150352086A1
(en)
|
2013-01-07 |
2015-12-10 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Heat shock protein (hsp) inhibition and monitoring effectiveness thereof
|
|
JOP20200097A1
(ar)
|
2013-01-15 |
2017-06-16 |
Aragon Pharmaceuticals Inc |
معدل مستقبل أندروجين واستخداماته
|
|
AU2014207311A1
(en)
|
2013-01-19 |
2015-08-20 |
New York University |
Oligooxopiperazines for p53 reactivation
|
|
EP2964245A4
(en)
|
2013-01-19 |
2016-09-21 |
Univ New York |
PEPTIDES AND PEPTIDOMIMETIC HYDROGEN-LINKED SUBSTITUTE FOR REACTIVATION OF P53
|
|
AU2014219256B2
(en)
|
2013-02-21 |
2017-02-16 |
Sunshine Lake Pharma Co., Ltd. |
Heteroaromatic compounds as PI3 kinase modulators
|
|
KR20150118159A
(ko)
|
2013-02-22 |
2015-10-21 |
에프. 호프만-라 로슈 아게 |
암의 치료 방법 및 약물 내성의 예방 방법
|
|
US20140243211A1
(en)
|
2013-02-28 |
2014-08-28 |
Indiana University Research & Technology Corporation |
Blood biomarkers for suicidality
|
|
CN109568312A
(zh)
|
2013-03-05 |
2019-04-05 |
田纳西大学研究基金会 |
用于治疗癌症的化合物
|
|
US9937161B2
(en)
|
2013-03-06 |
2018-04-10 |
The General Hospital Corporation |
Combinatorial compositions and methods for treatment of melanoma
|
|
BR112015022545A2
(pt)
|
2013-03-13 |
2017-07-18 |
Constellation Pharmaceuticals Inc |
compostos de pirazolo e os usos disso
|
|
WO2015073072A1
(en)
|
2013-11-15 |
2015-05-21 |
Oncoceutics, Inc. |
7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
|
|
PL2968294T3
(pl)
|
2013-03-13 |
2019-10-31 |
Oncoceutics Inc |
7-Benzylo-10-(2-metylobenzylo)-2,6,7,8,9,10-heksahydroimidazo[1,2-a]pirydo[4,3-d]pirymidyn-5(3H)-on do zastosowania w leczeniu nowotworu
|
|
BR112015023190A2
(pt)
|
2013-03-14 |
2017-07-18 |
Univ Florida |
regulação de câncer com o uso de compostos e/ou dieta naturais
|
|
WO2014160358A1
(en)
|
2013-03-14 |
2014-10-02 |
Thomas Cooper Woods |
Use of mir-221 and 222 lowering agents to prevent cardiovascular disease in diabetic subjects
|
|
CA2900951A1
(en)
|
2013-03-14 |
2014-10-02 |
Ratiopharm Gmbh |
Solid state forms of vemurafenib hydrochloride
|
|
WO2014145254A2
(en)
|
2013-03-15 |
2014-09-18 |
Sutter West Bay Hospitals |
Falz for use as a target for therapies to treat cancer
|
|
JP2016520528A
(ja)
|
2013-03-15 |
2016-07-14 |
ジェネンテック， インコーポレイテッド |
癌の治療及び抗癌剤耐性の防止方法
|
|
US20150018296A1
(en)
|
2013-03-15 |
2015-01-15 |
Golden Biotechnology Corporation |
Therapeutic methods and compositions utilizing cyclohexenone compounds
|
|
CA2904770A1
(en)
|
2013-03-15 |
2014-09-18 |
Sanofi |
Anti-tumoral composition comprising a pi3kbeta inhibitor and a raf inhibitor, to overcome cancer cells resistance
|
|
EP2971057A4
(en)
|
2013-03-15 |
2016-11-02 |
Kiyatec Inc |
BIOREACTOR SYSTEM
|
|
EP3434788B1
(en)
|
2013-03-15 |
2023-08-23 |
Life Technologies Corporation |
Classification and actionability indices for lung cancer
|
|
WO2014147611A1
(en)
|
2013-03-18 |
2014-09-25 |
Genoscience Pharma |
Quinolines derivatives as novel anticancer agents
|
|
US20160058751A1
(en)
|
2013-03-28 |
2016-03-03 |
Cellworks Group, Inc. |
Composition and method for treating cancer
|
|
US10220091B2
(en)
|
2013-04-04 |
2019-03-05 |
The General Hospital Corporation |
Combination treatments with sonic hedgehog inhibitors
|
|
KR20150141971A
(ko)
|
2013-04-08 |
2015-12-21 |
파마싸이클릭스 엘엘씨 |
이브루티닙 병용 요법
|
|
WO2014168721A2
(en)
|
2013-04-12 |
2014-10-16 |
Tufts Medical Center |
Methods and systems for designing and/or characterizing soluble lipidated ligand agents
|
|
AU2014253040A1
(en)
|
2013-04-13 |
2015-11-05 |
Universidade De Coimbra |
Platform for targeted delivery to stem cells and tumor cells and uses thereof
|
|
WO2014172046A2
(en)
|
2013-04-17 |
2014-10-23 |
Life Technologies Corporation |
Gene fusions and gene variants associated with cancer
|
|
US9556191B2
(en)
|
2013-04-28 |
2017-01-31 |
Sunshine Lake Pharma Co., Ltd. |
Aminoquinazoline derivatives and their salts and methods of use thereof
|
|
WO2014177915A1
(en)
|
2013-05-01 |
2014-11-06 |
Piramal Enterprises Limited |
Cancer combination therapy using imidazo[4,5-c]quinoline derivatives
|
|
US20140335077A1
(en)
|
2013-05-07 |
2014-11-13 |
Leonard Girnita |
Compositions and Methods for the Treatment of Cancer Using IGF-IR Antagonists and MAPK/ERK Inhibitors
|
|
US20160101106A1
(en)
|
2013-05-07 |
2016-04-14 |
Inhibikase Therapeutics, Inc. |
Methods for treating hcv infection
|
|
WO2014184211A1
(en)
|
2013-05-13 |
2014-11-20 |
Institut Gustave Roussy |
Prognosis and predictive biomarkers and biological applications thereof
|
|
WO2014193647A2
(en)
|
2013-05-26 |
2014-12-04 |
Calitor Sciences, Llc |
Alkenyl compounds and methods of use
|
|
SG11201509338QA
(en)
|
2013-05-30 |
2015-12-30 |
Plexxikon Inc |
Compounds for kinase modulation, and indications therefor
|
|
WO2014204856A1
(en)
|
2013-06-17 |
2014-12-24 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid anticancer derivatives and their uses
|
|
EP2815749A1
(en)
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
|
|
US9636328B2
(en)
|
2013-06-21 |
2017-05-02 |
Zenith Epigenetics Ltd. |
Substituted bicyclic compounds as bromodomain inhibitors
|
|
BR112015031073B1
(pt)
|
2013-06-21 |
2022-11-29 |
Zenith Epigenetics Ltd |
Compostos inibidores bicíclicos de bromodomínio e composição farmacêutica contendo os referidos compostos
|
|
TWI680760B
(zh)
|
2013-07-12 |
2020-01-01 |
印度商皮拉馬爾企業有限公司 |
治療黑色素瘤的藥物組合
|
|
US9751832B2
(en)
|
2013-07-30 |
2017-09-05 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Selective histone deactylase 6 inhibitors
|
|
WO2015017729A1
(en)
|
2013-07-31 |
2015-02-05 |
Virginia Tech Intellectual Properties, Inc. |
Dielectrophoresis methods for determining a property of a plurality of cancer cells
|
|
US20160166637A1
(en)
|
2013-08-02 |
2016-06-16 |
Virginia Tech Intellectual Properties, Inc. |
Methods of treating a cancer through targeted disruption of alpha connexin 43-zonula occludens-1 (zo-1) interaction
|
|
US20150056195A1
(en)
|
2013-08-23 |
2015-02-26 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Compositions and methods for inihibiting tumorigenicity of senescent cancer cells induced by chemotherapy
|
|
CN104415335A
(zh)
|
2013-09-02 |
2015-03-18 |
北京中康万达医药科技有限公司 |
体内个体化系统免疫治疗方法和装置
|
|
WO2015034519A1
(en)
|
2013-09-03 |
2015-03-12 |
University Of Virginia Patent Foundation |
Target peptides for immunotherapy and diagnostics
|
|
WO2015034729A1
(en)
|
2013-09-05 |
2015-03-12 |
Calitor Sciences, Llc |
Substituted pyridine compounds and methods of use
|
|
WO2015038649A1
(en)
|
2013-09-10 |
2015-03-19 |
Synta Pharmaceuticals Corp. |
Targeted therapeutics
|
|
EP3043819A4
(en)
|
2013-09-11 |
2017-04-05 |
Compugen Ltd. |
Anti-vstm5 antibodies and the use thereof in therapy and diagnosis
|
|
NZ718821A
(en)
|
2013-09-11 |
2022-07-01 |
Medimmune Ltd |
Anti-b7-h1 antibodies for treating tumors
|
|
WO2015036643A2
(es)
|
2013-09-13 |
2015-03-19 |
Sierra Jiménez Angels |
Marcador para predecir metástasis del cancer de mama
|
|
US11680297B2
(en)
|
2013-09-16 |
2023-06-20 |
The Johns Hopkins University |
Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells
|
|
US9695402B2
(en)
|
2013-09-17 |
2017-07-04 |
Yeda Research And Development Co. Ltd. |
ERK-derived peptides and uses thereof
|
|
EP3046557A1
(en)
|
2013-09-20 |
2016-07-27 |
Stichting Het Nederlands Kanker Instituut |
Rock in combination with mapk-pathway
|
|
WO2015041534A1
(en)
|
2013-09-20 |
2015-03-26 |
Stichting Het Nederlands Kanker Instituut |
P90rsk in combination with raf/erk/mek
|
|
US20150086509A1
(en)
|
2013-09-25 |
2015-03-26 |
The Trustees Of Columbia University In The City Of New York |
Compositions and methods for treating cancer using interferon and mapk pathway inhibitor
|
|
CN104513252B
(zh)
|
2013-09-26 |
2017-11-10 |
广东东阳光药业有限公司 |
取代脲衍生物及其在药物中的应用
|
|
JP6527508B2
(ja)
|
2013-10-01 |
2019-06-05 |
メディミューン リミテッド |
αＶβ６を過剰発現する癌を治療及び診断する方法
|
|
EP3052103A1
(en)
|
2013-10-04 |
2016-08-10 |
AB Science |
Method for determining the prognosis of pancreatic cancer
|
|
WO2015058056A1
(en)
|
2013-10-18 |
2015-04-23 |
The General Hospital Corporation |
N-methyl pyrazoloanthrone for treatment of cancer
|
|
US9585841B2
(en)
|
2013-10-22 |
2017-03-07 |
Tyme, Inc. |
Tyrosine derivatives and compositions comprising them
|
|
US9724657B2
(en)
|
2013-10-22 |
2017-08-08 |
Tyme, Inc. |
High-speed centrifugal mixing devices and methods of use
|
|
WO2015066452A2
(en)
|
2013-11-01 |
2015-05-07 |
Foundation Medicine, Inc. |
Methods of treating pediatric cancers
|
|
WO2015066439A2
(en)
|
2013-11-01 |
2015-05-07 |
Foundation Medicine, Inc. |
Methods of treating hematological malignancies
|
|
KR20160070188A
(ko)
|
2013-11-07 |
2016-06-17 |
데시페라 파마슈티칼스, 엘엘씨. |
암치료에 유용한 tie2 키나아제의 억제 방법
|
|
JP6637884B2
(ja)
|
2013-11-08 |
2020-01-29 |
ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド |
ブロモドメインおよびエクストラターミナル（ｂｅｔ）タンパク質インヒビターを使用するがんのための併用療法
|
|
WO2015070224A2
(en)
|
2013-11-11 |
2015-05-14 |
Amgen Inc. |
Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
|
|
BR112016010716A8
(pt)
|
2013-11-13 |
2020-04-22 |
Novartis Ag |
dose de reforço imunológico, baixa, de um inibidor de mtor, seu uso, e adjuvante de vacina
|
|
WO2015070280A1
(en)
|
2013-11-14 |
2015-05-21 |
Newsouth Innovations Pty Limited |
Senescence and senescence associated secretory phenotype
|
|
WO2015080867A1
(en)
|
2013-11-15 |
2015-06-04 |
New York University |
Method for predicting development of melanoma brain metastasis
|
|
US9717715B2
(en)
|
2013-11-15 |
2017-08-01 |
Samsung Electronics Co., Ltd. |
Method of combination therapy using an anti-C-Met antibody
|
|
CN110669047A
(zh)
|
2013-11-15 |
2020-01-10 |
昂克希尔迪克斯有限公司 |
用于治疗癌症的化合物、其组合物及应用方法
|
|
WO2015075749A1
(en)
|
2013-11-22 |
2015-05-28 |
Laurus Labs Private Limited |
Novel processes for the preparation of vemurafenib
|
|
GB201320729D0
(en)
|
2013-11-25 |
2014-01-08 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
|
CZ2013943A3
(cs)
|
2013-11-27 |
2015-06-03 |
Zentiva, K.S. |
Krystalické formy vemurafenibu
|
|
WO2015084804A1
(en)
|
2013-12-03 |
2015-06-11 |
Novartis Ag |
Combination of mdm2 inhibitor and braf inhibitor and their use
|
|
US20170000784A1
(en)
|
2013-12-08 |
2017-01-05 |
Van Andel Research Institute |
Autophagy Inhibitors
|
|
WO2015089380A2
(en)
|
2013-12-12 |
2015-06-18 |
Celcuity Llc |
Assays and methods for determining the responsiveness of an individual subject to a therapeutic agent
|
|
US20160319368A1
(en)
|
2013-12-17 |
2016-11-03 |
Csir |
A Method for Identification of Anti-HIV Human miRNA Mimics and miRNA Inhibitors and Anti-HIV Pharmaceutical Compounds
|
|
WO2015095842A2
(en)
|
2013-12-20 |
2015-06-25 |
Biomed Valley Discoveries, Inc. |
Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
|
|
CA3168002A1
(en)
|
2013-12-20 |
2015-06-25 |
Biomed Valley Discoveries, Inc. |
Cancer treatment using combinations of erk and raf inhibitors
|
|
EP3083583B1
(en)
|
2013-12-20 |
2020-11-18 |
Sagimet Biosciences Inc. |
Heterocyclic modulators of lipid synthesis and combinations thereof
|
|
US20160339023A1
(en)
|
2013-12-23 |
2016-11-24 |
Fang Li |
Pharmaceutical Combinations
|
|
TW201609805A
(zh)
|
2013-12-23 |
2016-03-16 |
美國禮來大藥廠 |
結合ｅｇｆｒ及ｍｅｔ之多功能抗體
|
|
JP6584322B2
(ja)
|
2013-12-27 |
2019-10-02 |
国立大学法人 東京医科歯科大学 |
アルツハイマー病及び前頭側頭葉変性症の診断方法、診断薬、治療薬、及びこれら薬剤のスクリーニング方法
|
|
WO2015101996A1
(en)
|
2014-01-02 |
2015-07-09 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to ceacam1 and kinase inhibitors for treating braf-mutated cells
|
|
NZ721780A
(en)
|
2014-01-07 |
2022-01-28 |
Sagimet Biosciences Inc |
Heterocyclic modulators of lipid synthesis for use against cancer and viral infections
|
|
WO2015104292A2
(en)
|
2014-01-07 |
2015-07-16 |
Biomedical Research Foundation Of The Academy Of Athens |
Compounds for use in treating or preventing cancerous diseases
|
|
EP3091970B1
(en)
|
2014-01-10 |
2020-10-28 |
Rgenix, Inc. |
Lxr agonists and uses thereof
|
|
US20170175197A1
(en)
|
2014-01-29 |
2017-06-22 |
Caris Mpi, Inc. |
Molecular profiling of immune modulators
|
|
EP3102190A4
(en)
|
2014-02-07 |
2017-09-06 |
Auspex Pharmaceuticals, Inc. |
Novel pharmaceutical formulations
|
|
IN2014MU00495A
(es)
|
2014-02-12 |
2015-09-25 |
Cipla Ltd |
|
|
US20150231069A1
(en)
|
2014-02-20 |
2015-08-20 |
Pankaj Modi |
Oral formulations of chemotherapeutic agents
|
|
CA2975829A1
(en)
|
2014-02-20 |
2015-09-03 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
|
|
KR20170008202A
(ko)
|
2014-02-21 |
2017-01-23 |
애브비 스템센트알엑스 엘엘씨 |
흑색종에 사용하기 위한 항-ｄｌｌ3 항체 및 약물 접합체
|
|
WO2015130922A2
(en)
|
2014-02-26 |
2015-09-03 |
The Trustees Of The University Of Pennsylvania |
Small molecule hsp70 inhibitors
|
|
WO2015135094A1
(en)
|
2014-03-13 |
2015-09-17 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
MA39483A
(fr)
|
2014-03-18 |
2015-09-24 |
Synta Pharmaceuticals Corp |
Agents thérapeutiques cibles
|
|
US20150269307A1
(en)
|
2014-03-18 |
2015-09-24 |
Texas Tech University System |
Target inhibition map system for combination therapy design and methods of using same
|
|
EP3122355A4
(en)
|
2014-03-26 |
2017-08-09 |
The Brigham and Women's Hospital, Inc. |
Compositions and methods for inhibiting bmp
|
|
EP3122354B1
(en)
|
2014-03-28 |
2022-06-15 |
Universita' degli Studi di Genova |
Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake
|
|
WO2015153657A2
(en)
|
2014-04-01 |
2015-10-08 |
Texas Tech University System |
Overcoming chemotherapeutic agent resistance in cancer by inhibiting mcl-1
|
|
US20170165240A1
(en)
|
2014-04-01 |
2017-06-15 |
Université Libre de Bruxelles |
New strategies for treating melanoma
|
|
WO2015153978A1
(en)
|
2014-04-04 |
2015-10-08 |
The University Of North Carolina At Chapel Hill |
Methods for the treatment of tumors
|
|
US10016421B2
(en)
|
2014-04-05 |
2018-07-10 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Histone deacetylase 6 inhibition for enhancing T-cell function during anti-tumor response and tumor-peptide vaccination
|
|
US10233170B2
(en)
|
2014-04-08 |
2019-03-19 |
Rigel Pharmaceuticals, Inc. |
2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use
|
|
CA2945129A1
(en)
|
2014-04-11 |
2015-10-15 |
The University Of North Carolina At Chapel Hill |
Mertk-specific pyrrolopyrimidine compounds
|
|
WO2015161230A1
(en)
|
2014-04-19 |
2015-10-22 |
Massachusetts Institute Of Technology |
Methods of reducing kinase inhibitor resistance
|
|
JP6500037B2
(ja)
|
2014-04-22 |
2019-04-10 |
キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ |
二環式ピラゾロン化合物および使用方法
|
|
EP3137117A4
(en)
|
2014-05-02 |
2018-04-04 |
The Wistar Institute Of Anatomy And Biology |
Combination therapies targeting mitochondria for cancer therapy
|
|
CN106535900A
(zh)
|
2014-05-06 |
2017-03-22 |
加利福尼亚大学董事会 |
使用braf抑制剂的伤口愈合
|
|
BR122023025321A2
(pt)
|
2014-05-13 |
2024-02-20 |
Medimmune Limited |
Uso de anticorpos anti-b7-h1 e anti-ctla-4
|
|
WO2015175965A1
(en)
|
2014-05-15 |
2015-11-19 |
The Research Foundation For Suny |
Compositions targeting the interaction domain between p27kip1 and brk and methods of use thereof
|
|
JP6818676B2
(ja)
|
2014-05-16 |
2021-01-20 |
アトリバ セラピューティクス ゲーエムベーハー |
インフルエンザウイルスおよび黄色ブドウ球菌の重感染に対する新規の抗感染戦略
|
|
WO2015178770A1
(en)
|
2014-05-19 |
2015-11-26 |
Stichting Het Nederlands Kanker Instituut |
Compositions for cancer treatment
|
|
WO2015179075A1
(en)
|
2014-05-21 |
2015-11-26 |
The Board Of Regents Of The University Of Texas System |
Treatment for melanoma
|
|
US20170189357A1
(en)
|
2014-05-23 |
2017-07-06 |
Duke University |
Methods of limiting morbidity in hemoglobinopathies
|
|
WO2015187512A1
(en)
|
2014-06-01 |
2015-12-10 |
Trovagene, Inc. |
Monitoring treatment of histiocytosis with vemurafenib and dabrafenib
|
|
US20170079979A1
(en)
|
2014-06-02 |
2017-03-23 |
Children's Hospital Medical Center |
Therapy for solid tumors
|
|
WO2015187499A1
(en)
|
2014-06-03 |
2015-12-10 |
Gilead Sciences, Inc. |
Use of an ask1 inhibitor for the treatment of liver disease, optionally in combination with a loxl2 inhibitor
|
|
JP2017516813A
(ja)
|
2014-06-03 |
2017-06-22 |
サインパス ファルマ, インク.Signpath Pharma, Inc. |
チャネル病を引き起こす薬物に対するｄｍｐｃ、ｄｍｐｇ、ｄｍｐｃ／ｄｍｐｇ、ｅｇｐｇ、ｌｙｓｏｐｇ及びｌｙｓｏｐｃの防御効果
|
|
EP3151829B1
(en)
|
2014-06-07 |
2019-10-02 |
Academia Sinica |
Novel sesquiterpene derivatives and their use in inflammation and cancer treatment
|
|
US10758526B2
(en)
|
2014-06-09 |
2020-09-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health |
Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
|
|
US11034757B2
(en)
|
2014-06-09 |
2021-06-15 |
Biomed Valley Discoveries, Inc. |
Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
|
|
US20230190750A1
(en)
|
2014-06-13 |
2023-06-22 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
|
JP2017517558A
(ja)
|
2014-06-13 |
2017-06-29 |
ジェネンテック， インコーポレイテッド |
癌薬剤耐性の治療方法及び防止方法
|
|
WO2015193702A1
(en)
|
2014-06-17 |
2015-12-23 |
Bionsil S.R.L. In Liquidazione |
Methods for determining the sensitivity or resistance of cancer cells to at least one anticancer drug and/or therapeutically active molecule
|
|
MX2016016667A
(es)
|
2014-06-23 |
2017-08-21 |
Genentech Inc |
Métodos para tratar el cáncer y prevenir la resistencia a fármacos contra el cáncer.
|
|
WO2016001830A1
(en)
|
2014-07-01 |
2016-01-07 |
Friedrich Miescher Institute For Biomedical Research |
Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
|
|
US9994577B2
(en)
|
2014-07-04 |
2018-06-12 |
Merck Patent Gmbh |
Azepanyl-derivatives and pharmaceutical compositions comprising the same with antiparasitic activity
|
|
US10166304B2
(en)
|
2014-07-11 |
2019-01-01 |
Regents Of The University Of Minnesota |
Antibody fragments for detecting cancer and methods of use
|
|
AU2015286569B2
(en)
|
2014-07-11 |
2021-04-15 |
Genmab A/S |
Antibodies binding AXL
|
|
WO2016008853A1
(en)
|
2014-07-14 |
2016-01-21 |
Universität Zürich Prorektorat Mnw |
Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor
|
|
CN106573060A
(zh)
|
2014-07-15 |
2017-04-19 |
豪夫迈·罗氏有限公司 |
使用pd‑1轴结合拮抗剂和mek抑制剂治疗癌症的组合物
|
|
HUE046008T2
(hu)
|
2014-07-17 |
2020-02-28 |
Sunshine Lake Pharma Co Ltd |
I-(5-terc-butil)-izoxazol-3-il)-3-(4-((feniI)-etinil)-fenil)-kabamid származékok, valamint az ezekkel rokon vegyületek FLT-3 inhibitorokként rák kezelésére
|
|
RU2704811C2
(ru)
|
2014-07-17 |
2019-10-31 |
БайоКьюрити Фармасьютикалз Инк. |
Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства
|
|
US20180064765A1
(en)
|
2014-07-18 |
2018-03-08 |
Advaxis, Inc. |
Listeria-based immunogenic compositions for eliciting anti-tumor responses
|
|
US10550439B2
(en)
|
2014-07-21 |
2020-02-04 |
Novellusdx Ltd. |
Methods for determining drug response of patient specific mutations
|
|
CN105294655B
(zh)
|
2014-07-26 |
2019-03-15 |
广东东阳光药业有限公司 |
Cdk类小分子抑制剂的化合物及其用途
|
|
JP6631616B2
(ja)
|
2014-07-26 |
2020-01-15 |
ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド |
ＣＤＫ阻害剤としての２−アミノ−ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン誘導体及びその使用
|
|
PT107846B
(pt)
|
2014-08-01 |
2019-03-22 |
Hovione Farm S A |
Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
|
|
EP3177595B1
(en)
|
2014-08-08 |
2021-02-24 |
The Trustees Of The University Of Pennsylvania |
Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy
|
|
EP3181136B1
(en)
|
2014-08-11 |
2019-11-27 |
The University of Tokyo |
Micelle containing epirubicin-complexed block copolymer and anti-cancer agent, and pharmaceutical composition containing said micelle applicable to treatment of cancer, resistant cancer or metastatic cancer
|
|
WO2016025648A1
(en)
|
2014-08-13 |
2016-02-18 |
Celgene Avilomics Research, Inc. |
Combinations of an erk inhibitor and a raf inhibitor and related methods
|
|
WO2016025651A1
(en)
|
2014-08-13 |
2016-02-18 |
Celgene Avilomics Research, Inc. |
Combinations of an erk inhibitor and a tor inhibitor and related methods
|
|
WO2016025650A1
(en)
|
2014-08-13 |
2016-02-18 |
Celgene Avilomics Research, Inc. |
Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
WO2016030455A1
(en)
|
2014-08-28 |
2016-03-03 |
Medimmune Limited |
Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer
|
|
CN107074824B
(zh)
|
2014-09-05 |
2021-01-08 |
基因泰克公司 |
作为用于治疗癌症的pcaf和gcn5抑制剂的式(i)的酞嗪衍生物
|
|
EP3191128A4
(en)
|
2014-09-11 |
2018-03-14 |
Celldex Therapeutics, Inc. |
Uses of anti-her3 antibodies for treating cancer
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
AP2017009771A0
(en)
|
2014-10-06 |
2017-02-28 |
Mayo Foundation |
Carrier-antibody compositions and methods of making and using the same
|
|
EP3204360B1
(en)
|
2014-10-10 |
2020-08-26 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
JP6783230B2
(ja)
|
2014-10-10 |
2020-11-11 |
ジェネンテック， インコーポレイテッド |
ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物
|
|
TW201625243A
(zh)
|
2014-10-14 |
2016-07-16 |
艾克塞里克斯公司 |
用於治療黑素瘤之藥物組合
|
|
WO2016061231A1
(en)
|
2014-10-14 |
2016-04-21 |
Deciphera Pharmaceuticals, Llc |
Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression
|
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
|
US20170326076A1
(en)
|
2014-10-27 |
2017-11-16 |
Centre National De La Recherche Scientifique |
Panicein compounds, compositions and uses thereof
|
|
EP3212228A2
(en)
|
2014-10-27 |
2017-09-06 |
Ruprecht-Karls-Universität Heidelberg |
Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
|
|
AU2015339137A1
(en)
|
2014-10-31 |
2017-05-25 |
Beth Israel Deaconess Medical Center |
Methods of detecting BRAF in cancer
|
|
US20170333404A1
(en)
|
2014-11-03 |
2017-11-23 |
Dispersol Technologies, Llc |
Improved formulations of vemurafenib and methods of making the same
|
|
EP3954375A1
(en)
|
2014-11-07 |
2022-02-16 |
AI Therapeutics, Inc. |
Apilimod for use in the treatment of colorectal cancer
|
|
MA40940A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
|
WO2016077375A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Bromodomain inhibitors and uses thereof
|
|
MA40943A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
|
WO2016075333A1
(en)
|
2014-11-14 |
2016-05-19 |
Vib Vzw |
Direct and selective inhibition of mdm4 for treatment of cancer
|
|
WO2016081281A1
(en)
|
2014-11-17 |
2016-05-26 |
Salk Institute For Biological Studies |
Lipophilic bisphosphonates and methods of use
|
|
JP6789941B2
(ja)
|
2014-11-21 |
2020-11-25 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
Ｔｇｆ−ベータ阻害剤としての縮合イミダゾール誘導体
|
|
RU2572569C1
(ru)
|
2014-11-27 |
2016-01-20 |
Федеральное государственное бюджетное научное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" (ФГБНУ "РОНЦ им. Н.Н. Блохина") |
СПОСОБ ПОЛУЧЕНИЯ ПОДКОЖНЫХ КСЕНОГРАФТОВ КЛЕТОЧНОЙ ЛИНИИ МЕЛАНОМЫ КОЖИ ЧЕЛОВЕКА mel Cher С МУТАЦИЕЙ V600E BRAF ДЛЯ ДОКЛИНИЧЕСКОГО ИЗУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ТАРГЕТНЫХ СРЕДСТВ
|
|
EP3632915A1
(en)
|
2014-11-27 |
2020-04-08 |
Genentech, Inc. |
4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
|
|
WO2016083956A1
(en)
|
2014-11-29 |
2016-06-02 |
Shilpa Medicare Limited |
Substantially pure vemurafenib and its salts
|
|
US10179125B2
(en)
|
2014-12-01 |
2019-01-15 |
Zenith Epigenetics Ltd. |
Substituted pyridines as bromodomain inhibitors
|
|
US10710992B2
(en)
|
2014-12-01 |
2020-07-14 |
Zenith Epigenetics Ltd. |
Substituted pyridinones as bromodomain inhibitors
|
|
WO2016089208A2
(en)
|
2014-12-04 |
2016-06-09 |
Stichting Maastricht Radiation Oncology "Maastro-Clinic" |
Sulfonamide, sulfamate and sulfamide derivatives of anti-cancer agents
|
|
WO2016092375A1
(en)
|
2014-12-11 |
2016-06-16 |
Zenith Epigenetics Corp. |
Substituted heterocycles as bromodomain inhibitors
|
|
US9862698B2
(en)
|
2014-12-16 |
2018-01-09 |
Adt Pharmaceuticals, Inc. |
Indenyl compounds, pharmaceutical compositions, and medical uses thereof
|
|
US10231953B2
(en)
|
2014-12-17 |
2019-03-19 |
Zenith Epigenetics Ltd. |
Inhibitors of bromodomains
|
|
US20190125745A1
(en)
|
2014-12-17 |
2019-05-02 |
Rgenix, Inc. |
Treatment and diagnosis of cancer
|
|
WO2016097870A1
(en)
|
2014-12-17 |
2016-06-23 |
Zenith Epigenetics Corp. |
Substituted bicyclic compounds as bromodomain inhibitors
|
|
WO2016097036A1
(en)
|
2014-12-17 |
2016-06-23 |
Karo Bio Ab |
Estrogen receptor ligand for use in treating melanoma
|
|
MA41217A
(fr)
|
2014-12-19 |
2017-10-24 |
Advaxis Inc |
Polythérapies ayant des souches de listeria recombinées
|
|
DE102014226903A1
(de)
|
2014-12-23 |
2016-06-23 |
Olympus Winter & Ibe Gmbh |
HF-Hilfsstoff, medizinisches System und Verfahren zum selektiven Behandeln von Krebsgewebe
|
|
TWI525110B
(zh)
|
2014-12-24 |
2016-03-11 |
財團法人工業技術研究院 |
聚合物、及包含其之醫藥組合物
|
|
ES2923602T3
(es)
|
2014-12-31 |
2022-09-28 |
Guardant Health Inc |
Detección y tratamiento de enfermedades que muestran heterogeneidad celular de enfermedad y sistemas y métodos para comunicar los resultados de las pruebas
|
|
CA2972919A1
(en)
|
2015-01-09 |
2016-07-14 |
Gilead Apollo, Llc |
Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
|
|
WO2016115218A1
(en)
|
2015-01-14 |
2016-07-21 |
The California Institute For Biomedical Research |
Antibody drug conjugates for the treatment of immune conditions
|
|
WO2016115376A1
(en)
|
2015-01-14 |
2016-07-21 |
The Regents Of The University Of California |
Detection and treatment of double drug resistant melanomas
|
|
WO2016116935A1
(en)
|
2015-01-21 |
2016-07-28 |
Yeda Research And Development Co. Ltd. |
Use of rasa2 as a prognostic and therapeutic marker for melanoma
|
|
EP3936141A3
(en)
|
2015-01-23 |
2022-03-23 |
Erasmus University Rotterdam Medical Center |
Anti-senescence compounds and uses thereof
|
|
WO2016123054A2
(en)
|
2015-01-26 |
2016-08-04 |
The University Of North Carolina At Chapel Hill |
Kinase drug combinations and methods of use thereof
|
|
CN107530298B
(zh)
|
2015-01-26 |
2021-06-04 |
耶鲁大学 |
利用酪氨酸激酶抑制剂的组合物和方法
|
|
WO2016123378A1
(en)
|
2015-01-30 |
2016-08-04 |
Kim Hyungsoo |
Cancer therapy using jak inhibitor in combination with mapk inhibitors
|
|
JP6636031B2
(ja)
|
2015-01-30 |
2020-01-29 |
ジェネンテック， インコーポレイテッド |
治療用化合物およびその使用
|
|
WO2016126878A2
(en)
|
2015-02-03 |
2016-08-11 |
The Trustees Of The University Of Pennsylvania |
Listeria-based immunomodulation
|
|
CN112494653A
(zh)
|
2015-02-05 |
2021-03-16 |
特尔诺沃有限公司 |
用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合
|
|
WO2016123679A1
(en)
|
2015-02-06 |
2016-08-11 |
Ferrao Petranel Theresa Christine |
A method of treatment
|
|
US20180021259A1
(en)
|
2015-02-10 |
2018-01-25 |
Memorial Sloan Kettering Cancer Center |
Dye-stabilized nanoparticles and methods of their manufacture and therapeutic use
|
|
US10052346B2
(en)
|
2015-02-17 |
2018-08-21 |
Cantex Pharmaceuticals, Inc. |
Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
|
|
MA41598A
(fr)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
|
WO2016139534A2
(en)
|
2015-03-02 |
2016-09-09 |
Strand Life Sciences Private Limited |
Apparatuses and methods for determining a patient's response to multiple cancer drugs
|
|
KR20170122799A
(ko)
|
2015-03-02 |
2017-11-06 |
리겔 파마슈티칼스, 인크. |
TGF-β 억제제
|
|
MX2017011196A
(es)
|
2015-03-03 |
2018-05-22 |
Biohaven Pharm Holding Co Ltd |
Farmacos precursores de riluzol y sus usos.
|
|
EP3265079A4
(en)
|
2015-03-03 |
2019-01-02 |
Caris MPI, Inc. |
Molecular profiling for cancer
|
|
WO2016139331A1
(en)
|
2015-03-05 |
2016-09-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of melanoma
|
|
CN107428728A
(zh)
|
2015-03-19 |
2017-12-01 |
3-V生物科学股份有限公司 |
脂质合成的杂环调节剂
|
|
RU2015110071A
(ru)
|
2015-03-23 |
2016-10-10 |
Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО "ФармТех" |
Применение новых химических соединений (варианты) в качестве ингибиторов nuak1 киназы для лечения онкологических заболеваний
|
|
PL3072529T3
(pl)
|
2015-03-26 |
2018-04-30 |
Ratiopharm Gmbh |
Kompozycja zawierająca wemurafenib i HPMC-AS
|
|
EP3072528B1
(en)
|
2015-03-26 |
2017-07-05 |
ratiopharm GmbH |
Composition comprising vemurafenib and cationic copolymer based on methacrylates
|
|
US20180078561A1
(en)
|
2015-03-31 |
2018-03-22 |
Lam Therapeutics, Inc. |
Active metabolites of apilimod and uses thereof
|
|
JP2016193848A
(ja)
|
2015-03-31 |
2016-11-17 |
東レ株式会社 |
Ｂｒａｆ阻害剤耐性メラノーマの治療又は予防剤
|
|
ES2918924T3
(es)
|
2015-04-01 |
2022-07-21 |
Rigel Pharmaceuticals Inc |
Inhibidores de TGF-beta
|
|
WO2016160833A1
(en)
|
2015-04-01 |
2016-10-06 |
Rigel Pharmaceuticals, Inc. |
TGF-β INHIBITORS
|
|
EP3280454A1
(en)
|
2015-04-07 |
2018-02-14 |
Memorial Sloan Kettering Cancer Center |
Nanoparticle immunoconjugates
|
|
WO2016164641A1
(en)
|
2015-04-08 |
2016-10-13 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
WO2016168264A1
(en)
|
2015-04-13 |
2016-10-20 |
Kiromic, Llc |
Methods and compositions for treating cancer with dendritic cells
|
|
WO2016168150A2
(en)
|
2015-04-13 |
2016-10-20 |
The Board Of Regents Of The University Of Texas System |
Treatment for cancer metastasis
|
|
CZ2015250A3
(cs)
|
2015-04-14 |
2016-10-26 |
Zentiva, K.S. |
Amorfní formy vemurafenibu
|
|
CN108138234A
(zh)
|
2015-04-15 |
2018-06-08 |
普罗麦迪奥股份有限公司 |
治疗骨髓增生性障碍的方法
|
|
WO2016168634A1
(en)
|
2015-04-17 |
2016-10-20 |
Bulldog Pharmaceuticals, Inc. |
Biomarkers related to treatment of cancer with her3 and egfr inhibitors
|
|
WO2016168721A1
(en)
|
2015-04-17 |
2016-10-20 |
The Trustees Of The University Of Pennsylvania |
Dimeric quinacrine derivatives as autophagy inhibitors for cancer therapy
|
|
AU2016252038B2
(en)
|
2015-04-20 |
2021-08-12 |
Effector Therapeutics, Inc. |
Inhibitors of immune checkpoint modulators for use in treating cancer and infections
|
|
WO2016174183A1
(en)
|
2015-04-30 |
2016-11-03 |
Bayer Pharma Aktiengesellschaft |
Combinations of inhibitors of irak4 with inhibitors of btk
|
|
EP3195865A1
(de)
|
2016-01-25 |
2017-07-26 |
Bayer Pharma Aktiengesellschaft |
Kombinationen von irak4 inhibitoren und btk inhibitoren
|
|
KR20160129609A
(ko)
|
2015-04-30 |
2016-11-09 |
삼성전자주식회사 |
Ｂｒａｆ 저해제를 포함하는 세포 또는 개체의 노화를 감소시키기 위한 조성물 및 그의 용도
|
|
WO2016179394A1
(en)
|
2015-05-05 |
2016-11-10 |
Malik Mohammad Tariq |
Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
|
|
WO2016182893A1
(en)
|
2015-05-08 |
2016-11-17 |
Teh Broad Institute Inc. |
Functional genomics using crispr-cas systems for saturating mutagenesis of non-coding elements, compositions, methods, libraries and applications thereof
|
|
US10568948B2
(en)
|
2015-05-13 |
2020-02-25 |
Agenus Inc. |
Vaccines for treatment and prevention of cancer
|
|
WO2016187122A1
(en)
|
2015-05-15 |
2016-11-24 |
University Of Iowa Research Foundation |
Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy
|
|
EP3298160B1
(en)
|
2015-05-20 |
2020-07-08 |
PamGene B.V. |
Method for predicting the response of melanoma patients to targeted pharmacotherapy
|
|
MX2017014700A
(es)
|
2015-05-20 |
2018-08-15 |
Broad Inst Inc |
Neoantigenos compartidos.
|
|
US9814714B2
(en)
|
2015-05-22 |
2017-11-14 |
Plexxikon Inc. |
Kinase modulation, and indications therefor
|
|
CN114807367A
(zh)
|
2015-05-27 |
2022-07-29 |
奎斯特诊断投资股份有限公司 |
用于筛选实体瘤的组合物和方法
|
|
WO2016196384A1
(en)
|
2015-05-29 |
2016-12-08 |
Fred Hutchinson Cancer Research Center |
Compositions for cellular immunotherapy
|
|
WO2016193955A1
(en)
|
2015-06-04 |
2016-12-08 |
Giorgio Stassi |
Combinations of kinase inhibitors for treating colorectal cancer
|
|
CN117257802A
(zh)
|
2015-06-05 |
2023-12-22 |
伊利诺伊大学董事会 |
Pac-1联合疗法
|
|
WO2016200688A1
(en)
|
2015-06-06 |
2016-12-15 |
Cloudbreak Therapeutics, Llc |
Compositions and methods for treating pterygium
|
|
WO2016200778A1
(en)
|
2015-06-08 |
2016-12-15 |
Children's Medical Center Corporation |
Methods for treatment of melanoma
|
|
WO2016200726A1
(en)
|
2015-06-08 |
2016-12-15 |
Texas Tech University System |
Inhibitors of mci-1 as drugs to overcome resistance to braf inhibitors and mek inhibitors
|
|
US20180311251A1
(en)
|
2015-06-10 |
2018-11-01 |
Epizyme, Inc. |
Ezh2 inhibitors for treating lymphoma
|
|
CA2988578A1
(en)
|
2015-06-12 |
2016-12-15 |
Indiana University Research & Technology Corporation |
Predicting suicidality using a combined genomic and clinical risk assessment
|
|
AU2016276963C1
(en)
|
2015-06-12 |
2021-08-05 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
EP3103450A1
(en)
|
2015-06-12 |
2016-12-14 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
None-hydrophobic compounds for use in treating metastasis and/or cartilage defect
|
|
AU2015242210A1
(en)
|
2015-06-15 |
2017-12-07 |
Hangzhou Dac Biotech Co., Ltd |
Hydrophilic linkers for conjugation
|
|
WO2015151079A2
(en)
|
2015-06-20 |
2015-10-08 |
Hangzhou Dac Biotech Co, Ltd |
Auristatin analogues and their conjugates with cell-binding molecules
|
|
WO2017004153A1
(en)
|
2015-06-29 |
2017-01-05 |
The Broad Institute Inc. |
Tumor and microenvironment gene expression, compositions of matter and methods of use thereof
|
|
AR105483A1
(es)
|
2015-06-30 |
2017-10-11 |
Exelixis Inc |
Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
|
|
EP4272735A1
(en)
|
2015-06-30 |
2023-11-08 |
Genentech, Inc. |
Immediate-release tablets containing a drug and processes for forming the tablets
|
|
EP3317246A4
(en)
|
2015-07-04 |
2019-02-27 |
Suzhou M-conj Biotech Co., Ltd. |
SPECIFIC CONJUGATION OF A CELL BINDING MOLECULE
|
|
US20180371550A1
(en)
|
2015-07-08 |
2018-12-27 |
Children's Hospital Medical Center |
Loss of transcriptional fidelity leads to immunotherapy resistance in cancers
|
|
EP3319965B1
(en)
|
2015-07-08 |
2022-05-04 |
Biomedical Research Foundation of the Academy of Athens |
Novel compounds for use in treating or preventing cancerous diseases
|
|
FI127517B
(sv)
|
2015-07-10 |
2018-08-15 |
Oy El Ho Ab |
Hydrauliska lösningar hos ett arbetsmaskin
|
|
EP3319993B1
(en)
|
2015-07-10 |
2020-01-15 |
Genmab A/S |
Axl-specific antibody-drug conjugates for cancer treatment
|
|
CA2991973C
(en)
|
2015-07-12 |
2021-12-07 |
Suzhou M-Conj Biotech Co., Ltd. |
Bridge linkers for conjugation of a cell-binding molecule
|
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
|
WO2017019520A1
(en)
|
2015-07-24 |
2017-02-02 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods of cerenkov targeted and activated imaging and therapeutics
|
|
WO2017019804A2
(en)
|
2015-07-28 |
2017-02-02 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
WO2017019664A1
(en)
|
2015-07-28 |
2017-02-02 |
University Of Iowa Research Foundation |
Compositions and methods of treating cancer
|
|
WO2017021857A1
(en)
|
2015-07-31 |
2017-02-09 |
Vascular Biogenics Ltd. |
Motile sperm domain containing protein 2 and cancer
|
|
CN116726183A
(zh)
|
2015-08-03 |
2023-09-12 |
Enb治疗公司 |
用于治疗与etbr激活相关的癌症的组合物和方法
|
|
AU2016302344A1
(en)
|
2015-08-06 |
2018-03-08 |
The Wistar Institute Of Anatomy And Biology |
Combination therapies targeting mitochondrial biogenesis for cancer therapy
|
|
WO2017023994A1
(en)
|
2015-08-06 |
2017-02-09 |
Yale University |
Small molecule based antibody-recruiting compounds for cancer treatment
|
|
MA45352A
(fr)
|
2015-08-07 |
2018-06-13 |
Univ Birmingham |
Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer
|
|
JP6817288B2
(ja)
|
2015-08-10 |
2021-01-20 |
ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． |
新規な連結体及び生体分子と薬物との特異的共役におけるその使用
|
|
WO2017176265A1
(en)
|
2016-04-06 |
2017-10-12 |
Mayo Foundation For Medical Education And Research |
Carrier-binding agent compositions and methods of making and using the same
|
|
EP3777978A1
(en)
|
2015-08-18 |
2021-02-17 |
Rakuten Medical, Inc. |
Phthalocyanine dye conjugates and their storage
|
|
AU2016308337B2
(en)
|
2015-08-18 |
2019-02-28 |
Mayo Foundation For Medical Education And Research |
Carrier-binding agent compositions and methods of making and using the same
|
|
WO2017031427A1
(en)
|
2015-08-19 |
2017-02-23 |
3-V Biosciences, Inc. |
COMPOUNDS AND METHODS FOR INHIBITING mTOR
|
|
US20170056327A1
(en)
|
2015-08-25 |
2017-03-02 |
The Methodist Hospital |
Micro/nano composite drug delivery formulations and uses thereof
|
|
US20190060309A1
(en)
|
2015-08-28 |
2019-02-28 |
Novartis Ag |
Mdm2 inhibitors and combinations thereof
|
|
JP6971970B2
(ja)
|
2015-09-03 |
2021-11-24 |
エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics, Inc. |
ペプチド模倣大環状分子およびその使用
|
|
US9771363B2
(en)
|
2015-09-21 |
2017-09-26 |
Plexxikon Inc. |
Heterocyclic compounds and uses thereof
|
|
US10016422B2
(en)
|
2015-09-30 |
2018-07-10 |
Oregon State University |
Nanocarrier drug delivery platform
|
|
WO2017059268A1
(en)
|
2015-10-01 |
2017-04-06 |
Mitchell Woods Pharmaceuticals, Inc. |
Methods of reducing chemoresistance and treating cancer
|
|
EP3355923B1
(en)
|
2015-10-01 |
2022-02-23 |
Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis |
Histone deacetylase inhibitors for use in the treatment of drug resistant melanoma
|
|
US9724393B2
(en)
|
2015-10-06 |
2017-08-08 |
The Wistar Institute Of Anatomy And Biology |
Method for treatment of metastatic and refractory cancers and tumors with an inducer that overcomes inhibition of T cell proliferation
|
|
WO2017066193A1
(en)
|
2015-10-15 |
2017-04-20 |
Princeton Drug Discovery, Llc |
Novel inhibitors of protein kinases
|
|
US10646576B2
(en)
|
2015-10-21 |
2020-05-12 |
Sprna Gmbh |
Immunostimulating-toxic RNA in alkaline earth metal formulation
|
|
WO2017067592A1
(en)
|
2015-10-21 |
2017-04-27 |
Biontech Ag |
Cytotoxic immunostimulating particles and uses thereof
|
|
CN114404581A
(zh)
|
2015-10-22 |
2022-04-29 |
摩登纳特斯有限公司 |
癌症疫苗
|
|
US20170115275A1
(en)
|
2015-10-23 |
2017-04-27 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Engineered substrates for high-throughput generation of 3d models of tumor dormancy, relapse and micrometastases for phenotype specific drug discovery and development
|
|
BR112018008918A8
(pt)
|
2015-11-02 |
2019-02-26 |
Univ Yale |
compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
|
|
CA3004530A1
(en)
|
2015-11-07 |
2017-05-11 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
|
|
WO2017083788A1
(en)
|
2015-11-14 |
2017-05-18 |
Sunshine Lake Pharma Co., Ltd. |
Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
|
|
WO2017083789A1
(en)
|
2015-11-14 |
2017-05-18 |
Sunshine Lake Pharma Co., Ltd. |
Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
|
|
KR20180081591A
(ko)
|
2015-11-19 |
2018-07-16 |
제넨테크, 인크. |
B-raf 억제제 및 면역 체크포인트 억제제를 사용하여 암을 치료하는 방법
|
|
EP3377894B1
(en)
|
2015-11-20 |
2019-12-25 |
Treat4Life AB |
Method for drug binding analysis in a tissue sample
|
|
WO2017089347A1
(en)
|
2015-11-25 |
2017-06-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
|
|
US20180369195A1
(en)
|
2015-11-30 |
2018-12-27 |
The Regents Of The University Of California |
Combination therapy for treatment of melanoma
|
|
WO2017091865A1
(en)
|
2015-12-03 |
2017-06-08 |
Alfred Health |
Monitoring treatment or progression of myeloma
|
|
WO2017099591A1
(en)
|
2015-12-07 |
2017-06-15 |
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis |
Treatment of inhibitor resistant braf-mutant cancers
|
|
SG11201804711RA
(en)
|
2015-12-07 |
2018-07-30 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
|
WO2017098336A1
(en)
|
2015-12-11 |
2017-06-15 |
Laurus Labs Private Limited |
Novel polymorphs of vemurafenib, process for its preparation and pharmaceutical composition thereof
|
|
WO2017106189A1
(en)
|
2015-12-14 |
2017-06-22 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ras/mapk mutant lung cancer
|
|
RU2018123481A
(ru)
|
2015-12-16 |
2020-01-20 |
Мерк Шарп И Доум Корп. |
Анти-lag3 антитела и антигенсвязывающие фрагменты
|
|
WO2017117182A1
(en)
|
2015-12-29 |
2017-07-06 |
Board Of Regents, The University Of Texas System |
Inhibition of p38 mapk for the treatment of cancer
|
|
WO2017117052A1
(en)
|
2015-12-31 |
2017-07-06 |
Effector Therapeutics, Inc. |
Mnk biomarkers and uses thereof
|
|
WO2017120600A1
(en)
|
2016-01-08 |
2017-07-13 |
Clearside Biomedical, Inc. |
Compositions and methods of treating wet age-related macular degeneration
|
|
WO2017127282A1
(en)
|
2016-01-19 |
2017-07-27 |
The General Hospital Corporation |
Cancer treatments and methods of selecting same
|
|
EP3199641B1
(en)
|
2016-01-27 |
2021-09-29 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Means and methods for staging, typing and treating a cancerous disease
|
|
JP2019503391A
(ja)
|
2016-01-29 |
2019-02-07 |
エピザイム，インコーポレイティド |
癌を処置するための併用療法
|
|
CN107709288A
(zh)
|
2016-02-03 |
2018-02-16 |
四川海思科制药有限公司 |
一种磷酰胺衍生物及制备方法和用途
|
|
WO2017136794A1
(en)
|
2016-02-03 |
2017-08-10 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
|
MY197069A
(en)
|
2016-02-04 |
2023-05-24 |
Sct Ii Llc |
Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
|
|
CA3013412C
(en)
|
2016-02-04 |
2023-10-10 |
Suzhou M-Conj Biotech Co., Ltd. |
Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
|
|
WO2017136741A1
(en)
|
2016-02-05 |
2017-08-10 |
Evol Science LLC |
Combinations to treat cancer
|
|
US20170226518A1
(en)
|
2016-02-09 |
2017-08-10 |
Autotelic Llc |
Compositions and methods for treating cancer
|
|
KR20180103817A
(ko)
|
2016-02-09 |
2018-09-19 |
오토텔릭 엘엘씨 |
암을 치료하기 위한 조성물과 방법
|
|
US11666656B2
(en)
|
2016-02-24 |
2023-06-06 |
Ramot At Tel-Aviv University Ltd. |
Polymeric conjugates and uses thereof
|
|
WO2017145179A1
(en)
|
2016-02-24 |
2017-08-31 |
Indian Institute Of Technology, Bombay |
Drug delivery system
|
|
US11725247B2
(en)
|
2016-02-29 |
2023-08-15 |
Foundation Medicine, Inc. |
Methods of treating cancer
|
|
EP3423055A4
(en)
|
2016-03-01 |
2019-10-16 |
Intezyne Technologies Inc. |
USE OF TRANS- [TETRACHLOROBIS (1H-INDAZOLE) RUTHENATE (III)] FOR THE TREATMENT OF CANCER
|
|
CN108884098B
(zh)
|
2016-03-08 |
2021-09-14 |
拜耳制药股份公司 |
2-氨基-N-[7-甲氧基-2,3-二氢咪唑并[1,2-c]喹唑啉-5-基]嘧啶-5-甲酰胺类
|
|
CN109069511A
(zh)
|
2016-03-10 |
2018-12-21 |
鲁特里斯制药有限公司 |
Braf抑制剂用于治疗皮肤反应的用途
|
|
WO2017161045A1
(en)
|
2016-03-16 |
2017-09-21 |
Plexxikon Inc. |
Compounds and methods for kinase modulation and indications therefore
|
|
WO2017161188A1
(en)
|
2016-03-16 |
2017-09-21 |
The Regents Of The University Of California |
Detection and treatment of anti-pd-1 therapy resistant metastatic melanomas
|
|
KR101921676B1
(ko)
|
2016-03-22 |
2018-11-26 |
한국과학기술원 |
Tesk1 억제제를 포함하는 항암제 내성 억제용 조성물 및 tesk1 억제제의 스크리닝 방법
|
|
WO2017162510A1
(en)
|
2016-03-24 |
2017-09-28 |
Bayer Pharma Aktiengesellschaft |
Substituted quinazolinone compounds for the treatment of proliferative diseases
|
|
WO2017176565A1
(en)
|
2016-04-07 |
2017-10-12 |
Eli Lilly And Company |
Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
|
|
US20190161523A1
(en)
|
2016-04-12 |
2019-05-30 |
Blaze Bioscience, Inc. |
Methods of treatment using chlorotoxin conjugates
|
|
CA3020854A1
(en)
|
2016-04-14 |
2017-10-19 |
Creatv Microtech, Inc. |
Methods of using pd-l1 expression in treatment decisions for cancer therapy
|
|
WO2017180820A1
(en)
|
2016-04-15 |
2017-10-19 |
The Penn State Research Foundation |
Compositions and methods for targeted delivery of therapeutic and/or diagnostic agents
|
|
AU2017249229A1
(en)
|
2016-04-15 |
2018-10-04 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
WO2017181149A1
(en)
|
2016-04-15 |
2017-10-19 |
Blaze Bioscience, Inc. |
Methods of treating breast cancer
|
|
WO2017184534A1
(en)
|
2016-04-18 |
2017-10-26 |
The Gorlin Companies |
Methods and compositions for improving safety and efficacy of natural killer cell immunotherapy
|
|
ES2886935T3
(es)
|
2016-04-25 |
2021-12-21 |
Forma Therapeutics Inc |
Inhibidores de FASN para su uso en el tratamiento de esteatohepatitis no alcohólica
|
|
US20200397894A1
(en)
|
2016-04-27 |
2020-12-24 |
University Of Virginia Patent Foundation |
Compositions and methods for treating cancer
|
|
JP2019112307A
(ja)
|
2016-04-28 |
2019-07-11 |
宇部興産株式会社 |
置換ジヒドロピロロピラゾール化合物および他の乾癬治療薬が組み合わせて投与される医薬組成物
|
|
WO2017193086A1
(en)
|
2016-05-06 |
2017-11-09 |
Tarrex Biopharma Inc. |
Therapeutic compounds and methods
|
|
WO2017196989A1
(en)
|
2016-05-10 |
2017-11-16 |
Unicorn Therapeutics, Llc |
Compositions of muscle stimulated myokines and methods of use thereof
|
|
EP3455753A1
(en)
|
2016-05-12 |
2019-03-20 |
F. Hoffmann-La Roche AG |
System for predicting efficacy of a target-directed drug to treat a disease
|
|
WO2017200826A1
(en)
|
2016-05-16 |
2017-11-23 |
Albert Einstein College Of Medicine, Inc. |
Assays and compounds for treatment of cancer
|
|
JP6103111B1
(ja)
|
2016-05-24 |
2017-03-29 |
三生医薬株式会社 |
経口医薬組成物及び該組成物からなる粒子状製剤の製造方法
|
|
MA45146A
(fr)
|
2016-05-24 |
2021-03-24 |
Constellation Pharmaceuticals Inc |
Dérivés de pyrazolopyridine pour le traitement du cancer
|
|
JP7160688B2
(ja)
|
2016-05-24 |
2022-10-25 |
ジェネンテック， インコーポレイテッド |
Ｃｂｐ／ｅｐ３００の複素環式インヒビターおよびがんの処置におけるそれらの使用
|
|
CA3025486A1
(en)
|
2016-05-25 |
2017-11-30 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
|
EP3463370A4
(en)
|
2016-05-27 |
2020-04-08 |
The Board of Regents of The University of Texas System |
6-THIO-2'-DESOXYGUANOSINE (6-THIO-DG) CAUSES TELOMERASE DEPENDENT TELEOMERS AND CELL DEATH IN THERAPY RESISTANT CANCER CELLS
|
|
AR108671A1
(es)
|
2016-06-03 |
2018-09-12 |
Enlibrium Inc |
Análogos de diamida imidodicarbonimidica
|
|
WO2017212420A1
(en)
|
2016-06-07 |
2017-12-14 |
Centre For Cellular And Molecular Platforms |
Methods and compositions for managing neuroinflammation and neurodegeneration
|
|
WO2017218365A1
(en)
|
2016-06-16 |
2017-12-21 |
Sunshine Lake Pharma Co., Ltd. |
Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
|
|
DK3471722T3
(da)
|
2016-06-17 |
2023-12-04 |
Univ Pennsylvania |
Forbindelser, sammensætninger og fremgangsmåder til forebyggelse og/eller behandling af cancer
|
|
GB201610628D0
(en)
|
2016-06-17 |
2016-08-03 |
Mihranyan Albert |
New compositions
|
|
TW201805000A
(zh)
|
2016-06-20 |
2018-02-16 |
庫拉腫瘤技術股份有限公司 |
利用erk抑制劑之鱗狀細胞癌之治療
|
|
EP3471701A4
(en)
|
2016-06-21 |
2020-02-19 |
The Regents of the University of California |
Wound healing with the help of Braf inhibitors
|
|
US11179484B2
(en)
|
2016-06-24 |
2021-11-23 |
University Of Iowa Research Foundation |
Compositions and methods of treating melanoma
|
|
EP3474849A4
(en)
|
2016-06-27 |
2020-07-29 |
The Broad Institute, Inc. |
COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF DIABETES
|
|
US11207392B2
(en)
|
2016-06-30 |
2021-12-28 |
Nantcell Inc. |
Coordinated multi-prong cancer therapy
|
|
RS60451B1
(sr)
|
2016-07-01 |
2020-07-31 |
Fermion Oy |
Novi postupci za dobijanje vemurafeniba
|
|
WO2018009528A1
(en)
|
2016-07-05 |
2018-01-11 |
Tdw Group |
Combination cancer immunotherapies with arginine depletion agents
|
|
WO2018009904A2
(en)
|
2016-07-08 |
2018-01-11 |
Tumeh Paul C |
Compositions and treatment methods for cancer immunotherapy
|
|
JP2019524713A
(ja)
|
2016-07-08 |
2019-09-05 |
ゲンマブ エー／エス |
抗ａｘｌ抗体に基づく抗体薬物コンジュゲートのための新しい投薬レジメン
|
|
US10711312B2
(en)
|
2016-07-12 |
2020-07-14 |
The Regents Of The University Of California |
Methods for immunotherapy-based treatment and assessment of cancer
|
|
US20180015075A1
(en)
|
2016-07-14 |
2018-01-18 |
Children's Hospital Medical Center |
Methods and compositions for treatment of venous malformation
|
|
EP3269365A1
(en)
|
2016-07-14 |
2018-01-17 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Kras inhibitor for use in treating cancer
|
|
CA2937896A1
(en)
|
2016-08-02 |
2018-02-02 |
Universite De Montreal |
Use of mubritinib for the treatment of poor prognosis acute myeloid leukemia
|
|
WO2018031707A1
(en)
|
2016-08-10 |
2018-02-15 |
Biohaven Pharmaceutical Holding Company Ltd. |
Acyl benzo[d]thiazol-2-amine and their methods of use
|
|
AU2017311927B2
(en)
|
2016-08-16 |
2021-06-03 |
National Institute Of Advanced Industrial Science And Technology |
Malignant tumor target peptide
|
|
EP3500686B1
(en)
|
2016-08-18 |
2024-01-10 |
Quest Diagnostics Investments LLC |
Methods for detecting craniopharyngioma and for selecting medicaments and patients for treatment
|
|
DK3506884T3
(da)
|
2016-08-30 |
2021-07-26 |
Dana Farber Cancer Inst Inc |
Sammensætninger til indgivelse af medicin og anvendelser af disse
|
|
MX2019002473A
(es)
|
2016-09-01 |
2019-09-18 |
Mayo Found Medical Education & Res |
Métodos y composiciones para el direccionamiento de cánceres de células t.
|
|
KR102462041B1
(ko)
|
2016-09-01 |
2022-11-02 |
메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 |
암 치료용 담체－ｐｄ－ｌ１ 결합제 조성물
|
|
WO2018049027A1
(en)
|
2016-09-07 |
2018-03-15 |
Trustees Of Tufts College |
Combination therapies using immuno-dash inhibitors and pge2 antagonists
|
|
WO2018049250A1
(en)
|
2016-09-08 |
2018-03-15 |
Curematch, Inc. |
Optimizing therapeutic options in personalized medicine
|
|
CN109715163B
(zh)
|
2016-09-19 |
2022-11-22 |
诺华股份有限公司 |
包含raf抑制剂和erk抑制剂的治疗组合
|
|
TW201815766A
(zh)
|
2016-09-22 |
2018-05-01 |
美商普雷辛肯公司 |
用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
|
|
EP3519436A4
(en)
|
2016-09-30 |
2020-09-09 |
Baylor College of Medicine |
TISSUE-ORIENTED ANTIBODY-BASED GENE THERAPY
|
|
WO2018071549A1
(en)
|
2016-10-11 |
2018-04-19 |
New York University |
Nanoparticles and uses thereof
|
|
IL248468A0
(en)
|
2016-10-13 |
2017-01-31 |
Technion Res & Dev Foundation |
Use of caspase-3 inhibitors and caspase-3 activators in the preparation of medical preparations for cancer treatment and wound healing
|
|
WO2018075447A1
(en)
|
2016-10-19 |
2018-04-26 |
The Trustees Of Columbia University In The City Of New York |
Combination of braf inhibitor, talimogene laherparepvec, and immune checkpoint inhibitor for use in the treatment cancer (melanoma)
|
|
KR20190042775A
(ko)
|
2016-10-19 |
2019-04-24 |
사인패스 파마 인코포레이티드 |
채널병증을 야기하는 약물에 대한 DMPC, DMPG, DMPC/DMPG, LysoPG 및 LysoPC의 보호 효과
|
|
US20200078360A1
(en)
|
2016-11-03 |
2020-03-12 |
The Regents Of The University Of Michigan |
Small molecule dual inhibitors of egfr/pi3k and uses thereof
|
|
MX2019005141A
(es)
|
2016-11-09 |
2019-09-26 |
Signpath Pharma Inc |
Efecto protector de dmpc, dmpg, dmpc/dmpg, lisopg y lisopc contra fármacos que causan canalopatías.
|
|
KR102459469B1
(ko)
|
2016-11-14 |
2022-10-26 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
|
US11441192B2
(en)
|
2016-11-15 |
2022-09-13 |
Quest Diagnostics Investments Llc |
Methods for detecting DNA mutations using mitra tip extraction
|
|
EP3541400A2
(en)
|
2016-11-18 |
2019-09-25 |
Sanford Burnham Prebys Medical Discovery Institute |
Gut microbiota and treatment of cancer
|
|
KR20190077476A
(ko)
|
2016-11-18 |
2019-07-03 |
뉴로바이브 파마슈티컬 에이비 |
상글리페린 거대고리 유사체의 항암 화합물로서의 용도
|
|
WO2018092064A1
(en)
|
2016-11-18 |
2018-05-24 |
Novartis Ag |
Combinations of mdm2 inhibitors and bcl-xl inhibitors
|
|
AU2017363257B2
(en)
|
2016-11-22 |
2021-08-19 |
Dana-Farber Cancer Institute, Inc. |
Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
|
|
WO2018095353A1
(en)
|
2016-11-25 |
2018-05-31 |
Sunshine Lake Pharma Co., Ltd. |
Salts of aminoquinazoline derivative and uses thereof
|
|
WO2018102769A1
(en)
|
2016-12-01 |
2018-06-07 |
Bluelink Pharmaceuticals, Inc. |
Treatment of cancer
|
|
US11473088B2
(en)
|
2016-12-02 |
2022-10-18 |
Ohio University |
Method of treating cancer and method of sensitizing cancer cells to the action of chemotherapeutic agents via growth hormone receptor antagonists or knock down
|
|
US11590133B2
(en)
|
2016-12-11 |
2023-02-28 |
Memorial Sloan Kettering Cancer Center |
Methods and compositions for treatment of BRAF mutant cancers
|
|
CN110381997A
(zh)
|
2016-12-12 |
2019-10-25 |
茂体外尔公司 |
用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物
|
|
WO2018118611A1
(en)
|
2016-12-19 |
2018-06-28 |
Nantbio, Inc. |
Methods and artificial tumors for validating an antitumor immune response
|
|
HUE055970T2
(hu)
|
2016-12-20 |
2022-01-28 |
Treat4Life Ab |
Eljárás BRAF mutációk és vad típusú BRAF fehérje meghatározására tömegspektrometria segítségével
|
|
CA3045744A1
(en)
|
2016-12-20 |
2018-06-28 |
Eth Zurich |
Identification of drugs targeting non-genetic drug tolerance programs in cancer
|
|
WO2018115888A1
(en)
|
2016-12-21 |
2018-06-28 |
N4 Pharma Uk Limited |
Novel formulations of aprepitant
|
|
BR112019012878A2
(pt)
|
2016-12-23 |
2019-11-26 |
Arvinas Operations Inc |
compostos e métodos para a degradação alvo de polipeptídos de fibrossarcoma rapidamente acelerados
|
|
TW201825087A
(zh)
|
2017-01-05 |
2018-07-16 |
杏國新藥股份有限公司 |
胰臟癌治療
|
|
FR3061658A1
(fr)
|
2017-01-07 |
2018-07-13 |
Guy Faustin Monkam Nitcheu |
Composition pharmaceutique comprenant en tant que principe actif une combinaison de d-limoneme, de lupeol et du cinnamaldehyde et/ou du methylhydroxychalcone polymere et/ou du beta-sitosterol et/ou de
|
|
WO2018132660A1
(en)
|
2017-01-13 |
2018-07-19 |
University Of Miami |
Integrator inhibitors and methods for their use
|
|
US11040027B2
(en)
|
2017-01-17 |
2021-06-22 |
Heparegenix Gmbh |
Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
|
|
TR201702500A2
(tr)
|
2017-02-20 |
2017-07-21 |
Anadolu Ueniversitesi |
Serani̇b-2?ni̇n akci̇ğer kanseri̇ ve meme kanseri̇ni̇n tedavi̇si̇nde kullanimi
|
|
US9861833B1
(en)
|
2017-03-30 |
2018-01-09 |
Norman H. Anderson |
Methods of treating melanoma
|